# Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer

> **NCT00585689** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** ABI-007
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine
- **PROCEDURE:** Radical Cystectomy

## Key facts

- **NCT ID:** NCT00585689
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2015-11-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00585689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00585689, "Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00585689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*